Catalio Capital Management LP Sells 29,625 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Catalio Capital Management LP trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,465 shares of the specialty pharmaceutical company’s stock after selling 29,625 shares during the period. Supernus Pharmaceuticals comprises approximately 2.4% of Catalio Capital Management LP’s investment portfolio, making the stock its 18th largest holding. Catalio Capital Management LP owned 0.45% of Supernus Pharmaceuticals worth $12,796,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Jefferies Financial Group Inc. lifted its position in Supernus Pharmaceuticals by 62.0% in the third quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 32,979 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in Supernus Pharmaceuticals in the third quarter worth $1,434,000. Phocas Financial Corp. purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth $4,042,000. Aberdeen Group plc purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth $13,497,000. Finally, Westover Capital Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth $1,587,000.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $43.58 on Thursday. The stock has a market capitalization of $2.53 billion, a PE ratio of -85.45, a P/E/G ratio of 0.93 and a beta of 0.55. The business has a 50 day simple moving average of $48.27 and a two-hundred day simple moving average of $49.51. Supernus Pharmaceuticals, Inc. has a 1-year low of $30.83 and a 1-year high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.